<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01848613</url>
  </required_header>
  <id_info>
    <org_study_id>IRST162.05</org_study_id>
    <secondary_id>2012-003544-68</secondary_id>
    <nct_id>NCT01848613</nct_id>
  </id_info>
  <brief_title>Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC</brief_title>
  <acronym>VIVOS</acronym>
  <official_title>Randomized Cross-over Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC. A Phase IV Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Title: Randomized cross-over study of patient preference for oral or intravenous vinorelbine&#xD;
      in the treatment of advanced NSCLC. A phase IV study.&#xD;
&#xD;
      ShortTitle/ Acronym: VIVOS&#xD;
&#xD;
      Protocol Code :IRST162.05&#xD;
&#xD;
      Study Design: Randomized, open label cross-over study&#xD;
&#xD;
      Study Duration: Two years&#xD;
&#xD;
      Study Center(s): Multicenter study&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      Primary: Patient preference for oral or intravenous vinorelbine Secondary: Overall Response&#xD;
      Rate, Time to Progression, Toxicity, Survival, Subjective reasons for treatment choice.&#xD;
&#xD;
      Number of Subjects: 120&#xD;
&#xD;
      Diagnosis and Main Inclusion Criteria:&#xD;
&#xD;
      Patients affected by stage IIIB or stage IV NSCLC candidates to receive a first line&#xD;
      chemotherapy with vinorelbine due to age ≥ 70 and Eastern Cooperative Oncology Group (ECOG)&#xD;
      Performance status ≤2 or age ≤ 70 but ECOG PS ≥ 2&#xD;
&#xD;
      Study Product, Dose, Route, Regimen and duration of administration :&#xD;
&#xD;
        -  Arm A: first cycle of IV vinorelbine (30 mg/m2) and second cycle of PO vinorelbine&#xD;
           (60mg/m2)&#xD;
&#xD;
        -  Arm B: first cycle with PO vinorelbine (60mg/m2) followed by a second cycle of IV&#xD;
           vinorelbine (30mg/m2) In both arms vinorelbine will be given at day 1 and day 8 every 3&#xD;
           weeks. From the third cycle onwards patients will have to choose to receive oral or&#xD;
           intravenous vinorelbine. Vinorelbine capsules will be administered at the dosage of 60&#xD;
           mg/m2 for the first course and then may be increased to 80 mg/m² at physician's choice.&#xD;
&#xD;
      Treatment will be repeated every 21 days and continued until disease progression, intolerable&#xD;
      toxicity or patient refusal.&#xD;
&#xD;
      Reference therapy: Vinorelbine 30 mg/m2 intravenous day 1 and 8 every 21 days&#xD;
&#xD;
      Statistical Methodology: The sample size is calculated based on 75% of patients preferring&#xD;
      &quot;oral&quot; vinorelbine and 25% preferring &quot;intravenous&quot; vinorelbine. Therefore, the investigators&#xD;
      would compare patients preferring &quot;oral&quot; vinorelbine as 75% compared to a null hypothesis of&#xD;
      50% (no difference in proportion of patients preferring &quot;oral&quot; to &quot;intravenous&quot;). With 80%&#xD;
      power and a total alpha of 0.05, the estimated sample size is 60 for group (120 total).&#xD;
      During recruitment period, a formal interim analysis was planned when 60 patients (30 for&#xD;
      group) have been enrolled, with a p-value &lt;0.0001. To claim statistical significance in the&#xD;
      final analysis, the overall p-value is still 5% (referred to Peto-Haybittle rule).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2012</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients preference for IV or PO vinorelbine.</measure>
    <time_frame>2 years</time_frame>
    <description>At the time of patient preference, a questionnaire will be filled in by patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (RR)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of both drug formulations</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective reasons for treatment choice</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Non-small Cell Lung Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>•Arm A: first cycle of IV vinorelbine (30 mg/m2) and second cycle of PO vinorelbine (60mg/m2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• Arm B: first cycle with PO vinorelbine (60mg/m2) followed by a second cycle of IV vinorelbine (30mg/m2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed stage IIIB or IV NSCLC.&#xD;
&#xD;
          2. Age ≥ 70 and Eastern Cooperative Oncology Group (ECOG) Performance status ≤2 or age ≤&#xD;
             70 but ECOG PS ≥ 2&#xD;
&#xD;
          3. Patients must have measurable disease, defined as at least one lesion that can be&#xD;
             accurately measured in at least one dimension (longest diameter to be recorded) as &gt;20&#xD;
             mm with conventional techniques or as &gt;10 mm with spiral CT scan. See section 9.2 and&#xD;
             Appendix E for the evaluation of measurable disease.&#xD;
&#xD;
          4. Patients with asymptomatic brain metastases are eligible&#xD;
&#xD;
          5. Patients with recurrent disease after previous surgery are eligible&#xD;
&#xD;
          6. Life expectancy &gt; 3 months&#xD;
&#xD;
          7. Patients must have normal organ and marrow function&#xD;
&#xD;
          8. Female participants of child bearing potential and male participants whose partner is&#xD;
             of child bearing potential must be willing to ensure that they or their partner use&#xD;
             effective contraception during the study and for 3 months thereafter&#xD;
&#xD;
          9. Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The participant may not enter the study if ANY of the following apply:&#xD;
&#xD;
          1. Patients who have had previous chemotherapy for lung cancer or radiotherapy on target&#xD;
             lesions.&#xD;
&#xD;
          2. Participation in another clinical trial with any investigational agents within 30 days&#xD;
             prior to study screening.&#xD;
&#xD;
          3. Presence of infection.&#xD;
&#xD;
          4. Preexisting clinically significant peripheral neuropathy.&#xD;
&#xD;
          5. History or evidence of malabsorption syndrome or disease that may significantly affect&#xD;
             gastrointestinal function.&#xD;
&#xD;
          6. Patients with known symptomatic uncontrolled brain metastases should be excluded from&#xD;
             this clinical trial because of their poor prognosis and because they often develop&#xD;
             progressive neurologic dysfunction that would confound the evaluation of neurologic&#xD;
             and other adverse events.&#xD;
&#xD;
          7. History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to vinorelbine or other agents used in the study.&#xD;
&#xD;
          8. Presence of medical problems of sufficient severity to prevent full compliance with&#xD;
             the study.&#xD;
&#xD;
          9. Other known malignant neoplastic diseases in the patient's medical history with a&#xD;
             disease-free interval of less than 5 years (except for previously treated basal cell&#xD;
             carcinoma and in situ carcinoma of the uterine cervix);&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Dazzi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UO Oncologia Medica, Ospedale S.Maria delle Croci, RAVENNA - ITALY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Irccs Irst</name>
      <address>
        <city>Meldola (FC)</city>
        <state>FC</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Oncologia Ospedale Civile degli Infermi</name>
      <address>
        <city>Faenza</city>
        <state>RA</state>
        <zip>48018</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Oncologia Ospedale Civile Umberto I</name>
      <address>
        <city>Lugo</city>
        <state>RA</state>
        <zip>48022</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Oncologia Medica, Ospedale S.Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <state>RA</state>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Oncologia Ospedale Cervesi</name>
      <address>
        <city>Cattolica</city>
        <state>RN</state>
        <zip>47841</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Oncologia ed Ematologia Oncologica ULSS 13 MIRANO</name>
      <address>
        <city>Mirano</city>
        <state>VE</state>
        <zip>30035</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Oncologia Medica ULSS 1 Belluno</name>
      <address>
        <city>Belluno</city>
        <zip>32100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Oncologia Ospedale degli Infermi</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>April 26, 2013</study_first_submitted>
  <study_first_submitted_qc>May 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2013</study_first_posted>
  <last_update_submitted>November 8, 2018</last_update_submitted>
  <last_update_submitted_qc>November 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

